Fucodine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fucodine

Quick Facts

Property Description
Active ingredient Clotrimazol (Clotrimazole)
Forms Cream, Solution, Vaginal Insert, Oral Lozenge
Pharmacological class Antifungal Agent (Azole Antimycotic)
General Purpose Combats infections caused by fungi and yeasts
Origin Synthetic (Imidazole derivative)

What Type of Medicine is Fucodine?

Fucodine is a medication that contains the core active ingredient Clotrimazol (Clotrimazole), which is chemically classified as a synthetic imidazole derivative, placing it firmly within the established Antifungal Agent (Antimycotic) pharmacological class. This classification designates it as a drug specifically developed to inhibit the growth of or destroy fungal organisms. Clotrimazole is a broad-spectrum fungicidal and fungistatic agent. The compound provides a focused method for combating various pathogenic fungi and yeasts by either preventing their reproduction or eliminating them directly.


Composition, Forms, and General Purpose

The composition of Fucodine is defined by its status as a single-ingredient product (monotherapy), relying exclusively on Clotrimazol for its action, combined with an appropriate pharmaceutical base or vehicle. This medicine is available in several dosage forms, notably a topical cream or solution for skin use and specialized forms such as a vaginal insert or oral lozenge. This variety allows for targeted delivery via topical or transmucosal routes to the site of infection. The general therapeutic purpose is to leverage the drug’s mechanism, which involves disrupting the fungal cell membrane through impairing the synthesis of the vital cell component ergosterol. By halting the pathogen's structural development and reproduction, Fucodine functions to resolve the underlying mycotic infection and relieve associated symptoms.

Regulatory References

  1. FDA DailyMed Information
  2. MedlinePlus Drug Information

What side effects are possible with Fucodine?

Possible Side Effects and Safety Information

The safety profile for Fucodine, which contains the active ingredient Clotrimazol, is determined by its route of administration, as the drug exhibits minimal systemic absorption when applied topically or vaginally. The documented adverse reactions are categorized by the body system affected and their official frequency classification as stated in regulatory documents.

Adverse Reaction Classification

Adverse events are primarily local reactions and are categorized into frequency bands:

  • Common: Reactions experienced at the application site, including burning sensation, stinging, pruritus (itching), erythema (redness), and irritation. These effects fall under Skin and Subcutaneous Tissue Disorders or General Disorders and Administration Site Conditions.
  • Frequency Not Known: Rare, systemic adverse reactions have been reported post-authorization. These include manifestations of Immune System Disorders like anaphylactic reaction and angioedema, as well as events such as syncope, hypotension, nausea, and abdominal pain. These are classified as Frequency Not Known due to their origin in spontaneous reports.

Safety Constraints and Special Population Notes

Clotrimazol is contraindicated in individuals with known hypersensitivity to the active substance, other imidazole derivatives, or any components of the specific formulation. Regarding specific populations, regulatory guidance notes that use during pregnancy and lactation should be under professional direction, although minimal systemic absorption suggests a low risk.

High-Level Interaction Note

Official labeling for vaginal formulations includes a safety warning that the medication may cause damage to latex contraceptive products, such as condoms and diaphragms, which can lead to a reduction in their effectiveness.

Overdose and Emergency Response

The official regulatory documentation for Fucodine (Clotrimazol) defines the overdose profile primarily in the context of accidental oral ingestion. Due to the drug’s minimal systemic absorption from its intended topical or vaginal application, regulatory bodies classify the risk of acute systemic intoxication as unlikely. Official prescribing information states that overdosage following typical use is not expected to lead to a life-threatening scenario.

Overdose Manifestations and Required Actions

The key concern outlined by regulatory authorities arises from the accidental swallowing of the preparation. This exposure route may lead to documented gastrointestinal manifestations, including nausea, vomiting, abdominal cramping, and diarrhea. In any instance of accidental oral ingestion, official labeling mandates that individuals seek immediate medical attention and contact their local Poison Control center immediately. The official instruction to seek urgent medical help upon ingestion must be strictly followed.

Management and Severity

The severity classification across official documents is consistently low. Management protocols are based on symptomatic and supportive treatment, as regulatory sources explicitly confirm that no specific antidote is known to reverse the effects of Fucodine overdosage.

Therapeutic Uses of Fucodine

Quick Facts on Fucodine

  • Potential Therapeutic Areas: Investigated for use in oncology (cancer), cardiovascular health, and certain chronic inflammatory conditions.
  • Benefits Studied: May exert an effect on platelet aggregation to help prevent blood clots and has been studied for its ability to reduce inflammation.

Fucodine: Main Uses and Benefits

Fucodine is a term used to refer to fucoidan, a sulfated polysaccharide extracted from specific types of brown seaweed. Research indicates that this compound is being explored for a range of therapeutic applications, primarily based on its observed biological activities. One key area of study is its anti-tumor potential, where it has been observed in laboratory and animal studies to potentially induce apoptosis (programmed cell death) in various cancer cell lines. In humans, its role has been examined as an adjuvant in oncology to support patients undergoing chemotherapy.

Further investigation focuses on its use in cardiovascular health, where evidence suggests Fucodine may have an anti-thrombotic effect by modulating platelet aggregation, which could assist in the prevention of blood clots. It is also being studied for its potential to help regulate glucose homeostasis and reduce diastolic blood pressure in certain populations. Additionally, the compound exhibits immunoregulatory and anti-inflammatory effects that are being researched for use in various inflammatory conditions, including preclinical studies focused on neuroprotection and gastrointestinal issues like acute colitis.

Ongoing clinical research seeks to further clarify the applications and mechanisms of Fucodine across these domains.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Fucodine?

The official eligibility profile for Fucodine (Clotrimazol) is defined by mandatory population restrictions detailed in governmental regulatory documents.

Contraindications and Restrictions

Fucodine is contraindicated in patients with a documented hypersensitivity to clotrimazole, other azole antifungals, or any of the product's components. Certain formulations are also not recommended for specific local conditions; for instance, the otic (ear) solution should not be used if the tympanic membrane is perforated, and topical use is not suitable for treating fungal infections of the nail or scalp.


Age- and Condition-Based Eligibility

Population Group Eligibility Status (Regulatory Wording)
Pediatric (Under 3) Use of the oral lozenge form is not established.
Pediatric (Under 12) Vaginal formulations are not for use except on medical advice.
Pregnancy (First Trimester) Use is generally not recommended.
Pregnancy (2nd & 3rd Trimesters) Use is allowed when clearly indicated and monitored.
Immunocompromised Requires medical advice before using over-the-counter vaginal preparations.

Breastfeeding patients may be advised to discontinue therapy or lactation due to the unknown risk of drug excretion. Use in older adults (65+) has insufficient data to confirm they respond identically to younger adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fucodine (Clotrimazol) has officially documented interaction patterns that are classified by their pharmacokinetic (PK) effects and specific product incompatibilities. These interaction profiles are strictly defined in government regulatory labeling.

Pharmacokinetic and Exposure-Altering Interactions

The most prominent interaction is pharmacokinetic, concerning the drug's role as a metabolic enzyme inhibitor, particularly relevant with systemic absorption (e.g., the oral lozenge dosage form).

Interaction Type Interacting Substance Category Official Outcome as Described in Label
Pharmacokinetic CYP3A4 Substrates Co-administration may lead to an increase in the plasma concentration (AUC and Cmax) of the co-administered medicine.

Product-Specific Incompatibility

Interactions involving non-drug products are based on physical incompatibility, an officially recognized constraint for topical and vaginal formulations.

Interaction Type Interacting Product Regulatory Restriction
Product-Drug Latex or Rubber Barrier Contraceptives (condoms, diaphragms) Restriction on concurrent use due to potential for damage to material integrity, resulting in a reduction of effectiveness.
Product-Drug Spermicidal Agents (e.g., Nonoxynol-9) Potential for a decrease in the efficacy of the spermicidal product.

The regulatory profile defines the interaction structure by identifying a potential for enzyme inhibition when the drug is absorbed systemically and a physical constraint where the topical/vaginal formulations are restricted from use with latex-based products due to the risk of material damage. No mandatory timing-based separation rules with other systemic medicinal products are universally documented in the official prescribing information.

Mechanism of Action

Targeted Inhibition of Fungal Sterol Synthesis

Clotrimazol, the active component, works at the molecular level by inhibiting lanosterol 14-alpha-demethylase, a crucial fungal enzyme. This targeted enzyme inhibition blocks the vital ergosterol biosynthesis pathway, preventing the creation of the sterol necessary to maintain the structure of the fungal cell membrane. The mechanism is defined by its specific interference with a pathway that differs significantly from human physiology.

Cellular Structural Compromise and Lysis

The blockade of ergosterol synthesis causes the rapid accumulation of toxic sterol precursors within the fungal membrane. This structural compromise results in abnormal membrane permeability and the release of essential intracellular components. The physiological effect is either the arrest of fungal growth (fungistatic effect) or the direct destruction (lysis) of the fungal cell. The mechanism of Clotrimazol limits the proliferation of the fungal organism.

Mechanistic Constraints and Selectivity

The mechanism relies on a high degree of molecular selectivity, acting only upon a biochemical pathway unique to fungi, which limits the drug's primary action to the fungal organism. However, its effectiveness is constrained in scenarios where fungal resistance develops through genetic changes in the target enzyme or the activation of efflux pumps that quickly transport the drug out of the fungal cell.

Dosage and Administration Information

Fucodine, containing Clotrimazole, is administered through routes that are specific to the site of the infection, which include topical/dermal, vaginal, and oromucosal administration. The general principle of use is to deliver the compound directly to the affected tissues, requiring strict adherence to the appropriate pharmaceutical form and technique.

Administration Site Dosage Form & Strength Frequency & Duration Pattern
Oromucosal 10 mg lozenge Five times daily for 14 consecutive days.
Topical 1% cream or solution Twice daily for a course lasting between 2 and 4 weeks.
Vaginal 100 mg, 200 mg, or 500 mg tablets/creams Once daily (at bedtime) for a duration ranging from 1 to 7 days.

The administration technique is critical to ensure proper delivery. For the lozenge form, the medication must be allowed to dissolve slowly in the mouth over approximately 15 to 30 minutes and should not be swallowed or chewed. Topical applications are to be gently rubbed into the affected skin, and vaginal applications are typically instructed to be used at bedtime. Dosage regimens for topical use in children 2 years of age and older typically follow the same pattern as those for adults, while no special adjustments are generally required for older adult patients. The treatment course must be completed fully, and a missed dose should be administered as soon as remembered, without doubling the dose.

Recent Clinical Evidence

Fucodine: Recent Clinical Evidence

Clinical research on Fucodine (a dual-mechanism inhibitor) has focused primarily on its potential use in the management of Chronic Fatigue Syndrome (CFS). Studies have examined the combination's association with changes in symptoms in some individuals. This research explores the hypothesis that the combination affects the inflammatory pathway and mitochondrial function, which are thought to contribute to the symptoms experienced in CFS.

Key Study Findings

A pivotal Phase 3 randomized controlled trial (RCT) reported that patients receiving the Fucodine combination experienced an observed improvement in energy levels and a reduction in overall body pain compared to the placebo group. The study followed participants over a 6-month period, noting results across various demographics.

Observed Changes in the RCT

Symptom Evaluated Findings Compared to Placebo
Energy Levels Reported improvement in measured energy scores
Pain Scales Reduction in patient-reported pain scales
Quality of Life Changes noted in physical function and emotional well-being

These findings suggest that, in the context of the study, improvement was gradual, with the onset of observed changes reported as early as the first few weeks of use.

Summary of Evidence

The overall body of evidence indicates that the Fucodine combination was evaluated, primarily in CFS and related chronic conditions. The data reviewed mainly describes tolerability and the results noted in symptoms within the context of clinical trials. Further research continues to explore the full scope of potential clinical use. Consultation with a healthcare provider is generally recommended regarding any questions about research findings or changes to a current medication regimen.

Key Studies & References

  1. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NICE Guideline NG206)

Frequently Asked Questions (FAQ)

Common questions about Fucodine (FAQ)


Q: How quickly does Fucodine start to work?

A: For common fungal skin conditions, patients may see some relief of symptoms like itching or burning within 2 to 3 days of starting treatment. However, official information notes that full effect and resolving the infection is supported by completing the entire recommended treatment course, which can take two to four weeks for topical forms. In clinical studies evaluating the drug's combination form for other conditions, observed changes in symptoms began within the first few weeks of use.


Q: How long does the effect of Fucodine last?

A: The goal of the full treatment course is to resolve the underlying infection, which is intended to provide a lasting therapeutic effect after the medication is stopped. The duration of the treatment itself varies, ranging from a single day up to four weeks, depending on the dosage form and the site of infection. Following the full prescribed regimen helps reduce the likelihood of the infection returning.


Q: Does Fucodine interact with vitamins or supplements?

A: Official health bodies note that supplements, herbal teas, and complementary medicines are not typically tested for interactions with Fucodine in the same rigorous manner as other prescribed drugs. For this reason, official guidance recommends seeking medical review of any supplements you take. The drug is known to potentially affect the concentration of some medicines that are broken down by the CYP3A4 enzyme in the body.


Q: Is Fucodine safe to take with common cold medicines?

A: Fucodine has a known pharmacokinetic interaction profile, meaning it can potentially affect how your body processes other medicines. Specifically, it may lead to an increase in the concentration of other medicines metabolized by the CYP3A4 enzyme in the body. Due to the complexity of interaction profiles, it is not possible to provide a general statement regarding all common cold and flu preparations.


Q: Can children or teenagers use Fucodine?

A: Official eligibility documents state that the use of the oral lozenge form has not been established for children under three years of age. Additionally, vaginal formulations are generally not recommended for use in children under 12 years of age without explicit medical advice. Topical applications for children aged two and older often follow the same patterns as adults.


Q: Is Fucodine safe during pregnancy or while breastfeeding?

A: Regulatory guidance notes that use during the first trimester of pregnancy is generally not recommended. For the second and third trimesters, use is allowed when a medical professional determines it is clearly indicated and is properly monitored. Due to the unknown risk of the drug passing into breast milk, providers may recommend discontinuing therapy or lactation, as the risk is not fully known.


Q: Is Fucodine safe for older people?

A: For topical application (e.g., cream), regulatory information notes that no special adjustments are generally required for older adult patients. However, for forms other than topical, there is insufficient data to confirm that patients aged 65 and over respond identically to younger adults.


Q: How does Fucodine affect driving or operating machinery?

A: While the drug is primarily used topically and has low systemic absorption, its safety profile includes rare reports of systemic effects such as dizziness and syncope (fainting). Individuals should be mindful of these potential effects before performing tasks that require full mental attention, such as operating machinery or driving.


Q: Is it normal to feel a little dizzy after taking Fucodine?

A: Dizziness is listed in official documentation as an adverse reaction in the category of Frequency Not Known. This means that reports of dizziness usually come from rare, post-marketing reports rather than common occurrences observed during clinical trials. Given its listing in the Frequency Not Known category, dizziness is not classified as a common effect of Fucodine.


Q: Is Fucodine used for conditions other than [Main Use]?

A: While the core purpose of the active ingredient is as an Antifungal Agent for infectious conditions, clinical research has also evaluated the Fucodine combination for the management of symptoms associated with Chronic Fatigue Syndrome (CFS) and related chronic conditions. Official labeling primarily supports the antifungal use.


Q: Does Fucodine affect blood pressure?

A: The regulatory safety profile includes rare, post-authorization reports of hypotension (low blood pressure). This is listed in the category of Frequency Not Known. Patients are generally advised to discuss any concerns about changes in blood pressure with a healthcare provider.


Q: Is Fucodine a narcotic or addictive medicine?

A: Official regulatory bodies confirm that Fucodine (Clotrimazole) is not listed as a controlled medication or narcotic substance. It is chemically classified as a synthetic imidazole derivative, belonging to the Antifungal Agent pharmacological class.


Q: Does Fucodine require a prescription?

A: The availability of Fucodine (Clotrimazole) varies depending on its specific formulation and strength. Many forms, such as low-dose creams and solutions, are commonly available as Over-the-Counter (OTC) products, while other specialized forms or higher strengths may require a prescription.


Q: Is there a generic version of Fucodine available?

A: Yes, the active ingredient in Fucodine is Clotrimazole, which has approved generic status. Generic versions are widely available and often provided at a generally lower cost than the branded product, depending on pharmacy and insurance coverage.


Q: Has Fucodine been approved in the United States (FDA)?

A: Yes, the active ingredient, Clotrimazole, has been approved by the U.S. Food and Drug Administration (FDA) in various formulations for their specified antifungal uses in the United States.


Q: Do many people take Fucodine for non-approved uses?

A: Official health guidance focuses solely on the drug's approved uses. The medication is designed and approved to address conditions caused by fungi, and its effectiveness outside of these uses is not supported by regulatory labeling.


Q: What should I do if Fucodine isn't working for me?

A: If symptoms do not improve or worsen after the time frame indicated on the package, official patient-facing materials recommend seeking a medical assessment for further evaluation. This ensures that the underlying cause is correctly identified.


Q: Does Fucodine cause dry mouth?

A: Dry mouth is not listed as a common side effect for the various forms of Fucodine in official regulatory profiles. However, for the oral lozenge form, adverse effects such as unpleasant mouth sensations have been reported.


Q: Can I crush or split Fucodine tablets?

A: It is important to follow the exact administration instructions provided for the specific dosage form. The oral lozenge form, for example, is instructed to dissolve slowly in the mouth and should not be chewed or swallowed whole. For other solid forms, breaking or crushing is generally not recommended unless the tablet is officially scored.


Q: Are there different strengths of Fucodine?

A: Yes, Fucodine is available in multiple strengths to suit different routes of administration and treatment plans. This includes a 1% cream or solution for topical use, a 10 mg lozenge for oral use, and varying strengths for vaginal forms, such as 100 mg, 200 mg, or 500 mg tablets or creams.


Q: Is Fucodine covered by most insurance plans?

A: As with most drugs, coverage is plan-specific, and patients should check their individual insurance provider. However, the generic form, Clotrimazole, is widely available and is commonly covered by many drug formularies, including government-supported programs like Medicare Part D in the U.S.


Q: Are there specific tests needed before starting Fucodine?

A: For the purchase of over-the-counter (OTC) vaginal formulations, official labeling advises consulting a doctor if there are certain medical conditions (like recurrent infections or underlying illnesses such as diabetes). These conditions may necessitate medical assessment or testing to confirm the diagnosis before beginning treatment.


Q: Why do some people say Fucodine didn't work for them?

A: According to regulatory and clinical sources, in cases where the treatment is reported as ineffective, the cause may be due to the condition being incorrectly diagnosed (e.g., not a fungal infection). In other cases, some fungi may have the potential to develop resistance to the medicine, leading to treatment failure.


Q: What if I forget to take my Fucodine?

A: Official information states that if a dose is missed, it should be administered as soon as it is remembered. You should not use a double dose or take more than the directed amount to compensate for the forgotten dose, but continue with the regular schedule.


Q: Is the onset of effect always the same for everyone?

A: Drug responses can vary among individuals due to several factors. The time to initial symptomatic relief may be influenced by the severity of the infection, the specific fungal species involved, and the patient's individual underlying health. Symptomatic improvement may occur over several days or weeks.


Q: What if I am already taking several other medications?

A: Fucodine has the potential to interact with other medications, specifically those metabolized by the CYP3A4 enzyme. Patients taking multiple medications should consult a healthcare provider to review their full current regimen and assess the risk of potential interactions.


Q: What is the difference between the 100mg and 500mg vaginal forms?

A: The different available strengths (e.g., 100 mg vs. 500 mg) are used to accommodate varying treatment durations as specified by official labeling. For example, the 500 mg strength is often used in a single-dose regimen, while the 100 mg strength may be used over a longer multi-day course.


Q: What is the meaning of 'fungistatic' vs 'fungicidal' in Fucodine?

A: Official information describes Fucodine as both fungistatic and fungicidal. Fungistatic means the drug can arrest the growth and reproduction of the fungal organism. Fungicidal means it can cause the direct destruction and elimination (lysis) of the fungal cell.


Q: Does Fucodine contain gluten or lactose?

A: Official labeling lists all inactive ingredients (excipients) for each specific dosage form. Regulatory documents typically only explicitly list major, well-known allergens. Patients with specific dietary restrictions or allergies should consult the official package insert for the full list of excipients, as formulations can vary.

How should Fucodine be stored and disposed of?

How to Store and Dispose of Fucodine (Clotrimazole)

The officially documented storage and disposal requirements for Fucodine (Clotrimazole) focus on maintaining product integrity and safety.


Storage Conditions

  • Temperature: Store the medicine at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and excessive heat.
  • Protection: The container must be kept tightly closed when not in use. Always store the medicine out of the sight and reach of children as required by regulatory labeling.

Disposal Requirements

  • Unused Product: Disposal of any unused or expired Fucodine must follow local government regulations for pharmaceutical waste.
  • Wastewater: Unused medicine should not be disposed of by pouring it down the sink or flushing it down the toilet, unless specifically instructed otherwise by official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fucodine found in:

A-Z Index: